Heart cancer exists, but it is one of the rarest cancers in the human body. Primary cardiac tumors occur at a rate of about 1.38 cases per 100,000 people per year, and only 25% of those are malignant. That means true heart cancer, a malignancy that originates in the heart itself, affects an extraordinarily small number of people worldwide.
Why Heart Cancer Is So Rare
The heart’s resistance to cancer comes down to biology. Cancer develops when cells divide uncontrollably, accumulating mutations along the way. But the muscle cells that make up most of the heart, called cardiac myocytes, stop dividing very early in life. They permanently exit the growth cycle and never re-enter it. After that point, the heart grows only because individual cells get larger, not because new cells are being produced.
This is a trade-off. The same trait that makes the heart nearly cancer-proof also makes it terrible at repairing itself after damage like a heart attack. As Dr. Deepak Srivastava of the Gladstone Institute of Cardiovascular Disease has explained, the tight control over cell division in heart muscle cells prevents them from proliferating to repair injured tissue, but it also makes them highly resistant to tumor formation. With so little cell division happening, the kind of runaway growth that characterizes cancer in organs like the lungs, colon, or breast simply doesn’t get a foothold in the heart.
Cancer That Starts in the Heart
When cancer does originate in the heart, it almost always arises not from the muscle cells themselves but from the cells lining blood vessels or the supportive tissue surrounding them. About 75% of malignant primary heart tumors are sarcomas, cancers of connective or vascular tissue.
The most common and aggressive type is angiosarcoma, which accounts for roughly 25% to 30% of all primary cardiac malignancies. Angiosarcoma starts in the cells lining the heart’s blood vessels and is characterized by rapid, abnormal blood vessel growth that invades and destroys healthy heart tissue. It is considered the most lethal form of primary heart cancer.
Other types include rhabdomyosarcomas (arising from muscle tissue) and fibrosarcomas (from fibrous tissue), but these are even rarer. There are no known genetic or lifestyle risk factors clearly linked to malignant cardiac tumors, unlike many other cancers.
Most Heart Tumors Are Not Cancer
About 75% of primary heart tumors are benign, meaning they don’t spread to other parts of the body. The most common benign heart tumor is a myxoma, a growth that typically forms in the upper left chamber of the heart. While myxomas aren’t cancerous, they can still cause serious problems by obstructing blood flow, triggering irregular heart rhythms, or sending fragments into the bloodstream that cause strokes. Benign tumors often require treatment, but the outlook after removal is generally very good.
Cancer That Spreads to the Heart
Far more common than cancer starting in the heart is cancer spreading to the heart from somewhere else. Metastatic cardiac tumors are 20 to 40 times more frequent than primary ones. Cancers of the lung, breast, skin (melanoma), blood (leukemia and lymphoma), and kidney are the most likely to metastasize to the heart. When cancer is found in the heart, the first question doctors investigate is whether it originated there or traveled from another site, because the two scenarios require very different treatment approaches.
Symptoms and How It’s Found
Heart tumors, whether benign or malignant, tend to produce vague symptoms that overlap with many common heart conditions. Shortness of breath, fatigue, swelling in the legs, chest pain, irregular heartbeat, and fainting spells are all possible. Some tumors cause fluid to build up around the heart, compressing it and reducing its ability to pump. Others block blood flow through the chambers or damage heart valves. In many cases, a heart tumor is discovered incidentally during imaging for something else entirely.
Echocardiography (a cardiac ultrasound) is typically the first tool used to spot a mass in the heart. It’s especially good at detecting small growths on heart valves and showing how blood flow is being affected. For more detail, cardiac MRI provides high-contrast images that help doctors determine what the mass is made of and whether it has invaded surrounding tissue. CT scans are useful for staging, helping to identify whether a malignant tumor has spread beyond the heart. In practice, doctors often use a combination of all three to get the full picture before planning treatment.
Treatment and Outlook
For primary heart cancers, surgery to remove the tumor is the main treatment when it’s feasible. Complete surgical removal leads to better outcomes than partial removal, but achieving it is often challenging. Tumors can wrap around or invade critical structures like heart valves, major blood vessels, or the walls between chambers. In one review of cardiac sarcoma surgeries, complete removal was achieved in about 67% of cases. When the tumor can’t be fully removed, surgeons may still perform a partial removal to relieve symptoms and improve heart function.
Chemotherapy and radiation are frequently used alongside surgery. Patients who received chemotherapy after surgical removal had a mean survival of about 12 to 13 months, while those who also received radiation therapy averaged around 14 months. These numbers reflect the aggressive nature of cardiac sarcomas, not inadequate treatment. There are currently no standardized treatment guidelines specifically for heart cancer, so care tends to be individualized at specialized centers.
The long-term prognosis for primary cardiac sarcoma is sobering. The five-year survival rate sits at roughly 10%. Two-year survival is around 48%, meaning outcomes drop sharply over time. For angiosarcoma specifically, the outlook is even worse in the short term, though five-year survival is comparable to other cardiac sarcomas at about 10%. By contrast, benign heart tumors like myxomas have excellent outcomes after surgical removal, with most patients returning to normal life.
How Rare Is Rare?
To put the numbers in perspective: in autopsy studies, primary heart tumors of any kind show up in 0.001% to 0.3% of cases. Only a quarter of those are malignant. You are far more likely to develop cancer in virtually any other organ. The heart’s unique biology, specifically its reliance on cells that stopped dividing decades ago, gives it a near-immunity to the unchecked growth that defines cancer. It’s one of the few genuine advantages of the heart’s otherwise limited ability to heal itself.